CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
Portfolio Pulse from
Candel Therapeutics' stock surged by 68% after the company announced that its Phase III study of CAN-2409 combination therapy for prostate cancer met its primary goal compared to standard-of-care radiation therapy.
December 12, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics' stock experienced a significant increase of 68% following the successful results of their Phase III study for CAN-2409 in treating prostate cancer.
The successful Phase III study results are a major milestone for Candel Therapeutics, indicating potential future revenue from CAN-2409. This positive news has led to a significant stock price increase, reflecting investor optimism.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100